US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly Gateway Laboratory (LGL) in China. This state-of-the-art facility, the fourth of its kind globally, is equipped with first-class ready-to-use laboratories, shared meeting rooms, and convenient workstations. The laboratory is designed to support the growth of early-stage biotechnology companies, promote scientific innovation, enhance drug development efficiency, and reduce the time to market for new drugs.
Facility Highlights
The LGL offers a comprehensive environment for biotech startups to thrive. The facility features advanced laboratory equipment, flexible meeting spaces, and modern office amenities, all aimed at creating an optimal environment for research and collaboration. By providing these resources, Eli Lilly aims to foster a vibrant ecosystem for scientific advancement and accelerate the development of novel therapies.
First Resident: 4B Technologies Investments Ltd
China-based 4B Technologies Investments Ltd, a biotech company focused on central nervous system (CNS) drug development, is the first resident of the Beijing incubator. The company has four novel drugs at clinical stages and has established research and development platforms for animal models of neurological diseases and cerebral organoids. This residency marks a significant step for 4B Technologies in advancing its CNS drug pipeline and leveraging the LGL’s resources to accelerate its development efforts.-Fineline Info & Tech
Leave a Reply